Netarsudil significantly reduces intraocular pressure in patients

PDF) Two Phase 3 clinical trials comparing the safety and efficacy

Netarsudil as an additional therapy for glaucoma

Diurnal intraocular pressure reduction with latanoprost 0.005

A Guide to Applying IOP-lowering Drugs

Aerie reports positive phase 3 results for netarsudil 0.02% vs

Advancements in Treatment of Open-Angle Glaucoma

Anti-fibrotic activity of a rho-kinase inhibitor restores outflow

CME; bimatoprost implant, netarsudil, latanoprost, Rocklatan

Netarsudil lowers IOP in glaucoma, ocular hypertension

An overview of new glaucoma medications - EyeWorld

CRSToday Newly Approved Glaucoma Therapy Increases Options for

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular

FDA Committee Backs Netarsudil, a Once-Daily Glaucoma Drug